Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
01 Dec 2015
More acromegalic patients presented with thyroid autoimmunity than the normal population as shown in a retrospective study.
Pearl Toh, 5 days ago
Zoledronate significantly reduces the risk of both nonvertebral and vertebral fragility fractures over 6 years in older women with osteopenia — a substantial patient group at risk for fractures but in whom a knowledge gap remains for pharmacological treatment, reveals a large randomized trial.
01 Feb 2016
The SAGIT instrument, a comprehensive clinician-reported outcome instrument, is a potential device for the assessment and management of acromegaly, based on a pilot study.

No clear benefits with tight glycaemic control in critically ill children

Jairia Dela Cruz
01 Sep 2018

Tight glycaemic control (TGC) does not yield significant short-term survival gains and risk reductions for infections when compared with a conventional glucose-lowering strategy in critically ill patients in the paediatric intensive care unit, according to a meta-analysis.

Pooled data from five randomized controlled trials of TGC with insulin therapy vs conventional glucose monitoring (CGC) in a total of 3,933 critically ill children—including those who were severely burnt and who underwent cardiac surgery, among others—revealed that TGC had no significant effect on the primary outcome of 30-day mortality rates (odds ratio [OR], 0.99; 95 percent CI, 0.74–1.32; p=0.95). [Pediatr Res 2018;83:930-935]

Results were similar for the secondary outcome of healthcare-associated infections, with rates being slightly lower with TGC but not significantly different vs CGC (OR, 0.80; 0.64–1.00 p=0.05).

Additionally, hypoglycaemia occurred as a major complication of glucose control in all five trials. Children in the TGC group were six times as likely as those in the CGC group to develop the condition (OR, 6.37; 4.41–9.21; p<0.001).

No publication bias was detected among the studies.

The authors pointed out that although TGC may bring clinical benefits in theory, the strategy did not show obvious survival benefits compared with CGC in critically ill children. The null effect may be partially attributed to the heterogeneity of critical degrees of patients.

Meanwhile, the failure to reduce infection rates with TGC was probably due to the complicated condition of the children. “For example, insulin therapy may exert more obvious anti-inflammatory effect in obese or diabetic patients. Discrepancy [between] susceptibility to infection and different antibiotic regimens used in trials may also contribute to this result,” they added.

The results of the present meta-analysis should be interpreted with caution, given the heterogeneity of the included studies, the authors said. Additional investigations with long-term follow-up are also warranted to explore the association of TGC and hypoglycaemia with neurodevelopmental outcomes.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 16 Oct 2018
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
01 Dec 2015
More acromegalic patients presented with thyroid autoimmunity than the normal population as shown in a retrospective study.
Pearl Toh, 5 days ago
Zoledronate significantly reduces the risk of both nonvertebral and vertebral fragility fractures over 6 years in older women with osteopenia — a substantial patient group at risk for fractures but in whom a knowledge gap remains for pharmacological treatment, reveals a large randomized trial.
01 Feb 2016
The SAGIT instrument, a comprehensive clinician-reported outcome instrument, is a potential device for the assessment and management of acromegaly, based on a pilot study.